Ristocetin A (sulfate) (Synonyms: Ristomycin III) |
| Katalog-Nr.GC16058 |
antibiotic that was used to treat staphylococcal infections
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 90831-71-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ristocetin A, a glycopeptide related to vancomycin, is an antibiotic produced by the microorganism Nocardia lurida[1].
Ristocetin A is currently in clinical use to treat bacterial infections [1]. Ristocetin A is an antibiotic which can be used to treat staphylococcal infections. The side effects of ristocetin A include thrombocytopenia and platelet agglutination. Ristocetin A has been used in two assays: the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. These two assays could be used to diagnosis the von Willebrand disease and other bleeding disorders [2, 3]. The structural features of Ristocetin A are similar to vancomycin.
References:
[1] Pearson A J, Heo J N. Approaches to the fully functionalized DEF ring system of ristocetin A via highly selective ruthenium-promoted SNAr reaction[J]. Organic letters, 2000, 2(19): 2987-2990.
Hawks G H. Antibiotic therapy of staphylococcal infections[J]. Canadian Medical Association journal, 1965, 93(16): 848.
[3] Castaman, G. ,Hillarp, A. and Goodeve, A. Laboratory aspects of von Willebrand disease: Test repertoire and options for activity assays and genetic analysis. Haemophilia 20(suppl 4), 65-70 (2014).
| Cas No. | 90831-71-3 | SDF | |
| Überlieferungen | Ristomycin III | ||
| Chemical Name | ristomycin A, monosulfate | ||
| Canonical SMILES | CC1C(O)C(N)CC(OC2C3C(NC(C(OC)=O)C4=CC(O)=CC(OC5C(O)C(O)C(O)C(CO)O5)=C4C6=C(O)C=CC(C(NC(C7C8=CC(OC9=CC=C(C(O)C%10C(NC(C(N7)=O)C%11=CC(OC%12=C(O)C=CC(C(N)C(N%10)=O)=C%12)=C(C)C(O)=C%11)=O)C=C9)=C(OC%13C(OC%14C(OC%15C(O)C(O)C(O)CO%15)C(O)C(O)C(CO)O%14)C(O)C( | ||
| Formula | C95H112N8O44 • SO4 | M.Wt | 2166 |
| Löslichkeit | DMF: Soluble,DMSO: Soluble,Ethanol: Soluble,Methanol: Soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.4617 mL | 2.3084 mL | 4.6168 mL |
| 5 mM | 0.0923 mL | 0.4617 mL | 0.9234 mL |
| 10 mM | 0.0462 mL | 0.2308 mL | 0.4617 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *